Meeting
2022 ASCO Annual Meeting
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
Authors
Dejan Juric
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Dejan Juric , Hope S. Rugo , Stephen K.L. Chia , Florence Lerebours , Manuel Ruiz-Borrego , Pamela Drullinsky , Eva M. Ciruelos , Patrick Neven , Yeon Hee Park , Christina H. Arce , Ennan Gu , Mukta Joshi , Estelle Roux , Murat Akdere , Nicholas C. Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1018)
DOI
10.1200/JCO.2022.40.16_suppl.1018
Abstract #
1018
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
First Author: Hope S. Rugo
Poster
2021 ASCO Annual Meeting
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
First Author: Stephen K. L. Chia
Poster
2022 ASCO Quality Care Symposium
Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
First Author: Emily J. Gallagher
Poster
2023 ASCO Annual Meeting
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.
First Author: Stephen Chia